Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EDSA

EDSA - Edesa Biotech Inc Stock Price, Fair Value and News

$1.75+0.02 (+1.16%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

EDSA Price Action

Last 7 days

2.3%

Last 30 days

0.6%

Last 90 days

-30.8%

Trailing 12 Months

-28.3%

EDSA RSI Chart

EDSA Valuation

Market Cap

12.3M

Price/Earnings (Trailing)

-2.08

Price/Sales (Trailing)

21.46

EV/EBITDA

0.01

Price/Free Cashflow

-1.88

EDSA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EDSA Fundamentals

EDSA Revenue

Revenue (TTM)

574.0K

Rev. Growth (Yr)

-22.41%

Rev. Growth (Qtr)

250.66%

EDSA Earnings

Earnings (TTM)

-5.9M

Earnings Growth (Yr)

-4.87%

Earnings Growth (Qtr)

-10%

EDSA Profitability

Operating Margin

100.00%

EBT Margin

-1040.04%

Return on Equity

-41.88%

Return on Assets

-39.98%

Free Cashflow Yield

-53.33%

EDSA Investor Care

Shares Dilution (1Y)

116.72%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025626.9K574.0K00
2024639.7K669.0K698.3K878.6K
202300581.0K610.3K
20224.0M2.6M780.3K0
20217.4M8.6M10.3M11.1M
2020576.2K568.4K328.8K0
2019298.1K0465.1K518.7K
2018108.0K160.5K211.8K244.4K
2017662.1K501.5K228.3K106.9K
20161.2M1.2M1.3M925.4K
2015604.1K681.4K758.7K1.0M
2014387.0K379.6K372.1K526.8K
201300409.4K402.0K
201200286.1K0
Get all data in R, Python etc through our Historical Stock Data APIs

About Edesa Biotech Inc

EDSA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
 CEO
 WEBSITEedesabiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Edesa Biotech Inc Frequently Asked Questions

What is the ticker symbol for Edesa Biotech Inc? What does EDSA stand for in stocks?

EDSA is the stock ticker symbol of Edesa Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edesa Biotech Inc (EDSA)?

As of Wed Dec 03 2025, market cap of Edesa Biotech Inc is 12.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDSA stock?

You can check EDSA's fair value in chart for subscribers.

Is Edesa Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether EDSA is over valued or under valued. Whether Edesa Biotech Inc is cheap or expensive depends on the assumptions which impact Edesa Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDSA.

What is Edesa Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, EDSA's PE ratio (Price to Earnings) is -2.08 and Price to Sales (PS) ratio is 21.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDSA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Edesa Biotech Inc's stock?

In the past 10 years, Edesa Biotech Inc has provided -0.517 (multiply by 100 for percentage) rate of return.